Compare OHI & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OHI | RDY |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.6B |
| IPO Year | 2001 | 2001 |
| Metric | OHI | RDY |
|---|---|---|
| Price | $44.54 | $13.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $46.55 | $16.90 |
| AVG Volume (30 Days) | ★ 2.3M | 1.3M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.74% | 0.52% |
| EPS Growth | ★ 25.16 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $1,190,099,000.00 | N/A |
| Revenue This Year | $4.70 | $7.72 |
| Revenue Next Year | $5.38 | $3.50 |
| P/E Ratio | $94.77 | ★ $18.67 |
| Revenue Growth | ★ 13.19 | N/A |
| 52 Week Low | $35.70 | $12.19 |
| 52 Week High | $49.33 | $15.38 |
| Indicator | OHI | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 46.48 |
| Support Level | $43.27 | $12.86 |
| Resistance Level | $45.72 | $13.54 |
| Average True Range (ATR) | 1.18 | 0.18 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 33.47 | 52.43 |
Omega Healthcare Investors Inc is a real estate investment trust that invests in healthcare-related real estate properties located in the United States (U.S.), the United Kingdom (U.K.), and Canada. The company's objective is to provide attractive returns to investors while serving as the preferred capital partner to its third-party healthcare operating companies and affiliates, as well as other third-party healthcare operators, allowing them to focus on delivering a high level of care to their resident patients. Omega's investment portfolio mainly consists of skilled nursing facilities, assisted living facilities (ALFs), including care homes in the U.K., independent living facilities, rehabilitation and acute care facilities, and continuing care retirement communities.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.